Neuro-Oncology News

A high percentage of patients undergoing treatment for cancer achieved a sufficient antibody response to the BNT162b2 messenger RNA COVID-19 vaccine, according to study results published in JAMA Oncology.

Olaparib monotherapy appeared well-tolerated and demonstrated evidence of antitumor activity among patients with heavily pretreated isocitrate dehydrogenase-mutant high-grade glioma, according to results of the phase 2 OLAGLI study.

Chimeric antigen receptor T cells have emerged “as a promising therapeutic avenue” for the treatment of glioblastoma, though various factors still limit its efficacy, according to a review published in Neurology.

Dabrafenib plus trametinib exhibited encouraging activity among patients with recurrent or refractory BRAF V600E mutation-positive glioma, according to study results.

Morning administration of temozolomide appeared associated with longer OS compared with evening administration among patients with newly diagnosed glioblastoma, according to study results published in Neuro-Oncology Advances.

Three of four patients who received an investigational chimeric antigen receptor T-cell therapy for diffuse midline glioma showed tumor regression and improvement in neurologic symptoms, according to early results of a phase 1 study.

Michael E. Salacz, MD, has been appointed director of the neuro-oncology program at Rutgers Cancer Institute of New Jersey.

The FDA granted orphan drug designation to CYNK-001 for the treatment of malignant gliomas, according to the agent’s manufacturer.

American Association for Cancer Research presented its AACR Team Science Award to the St. Baldrick’s Foundation-Stand Up To Cancer Pediatric Cancer Dream Team.

Use of a modified herpesvirus with and without radiation showed promising efficacy and safety for the treatment of children with recurrent or progressive high-grade glioma, according to results of a phase 1 trial.